Figure 1.

We performed RNA sequencing on pre-treatment biopsies from 43 patients with operable TNBC who received sequential taxane-and anthracycline-based neoadjuvant chemotherapy. At greater than 5 year median follow-up, 14 patients recurred and of those all but 2 patients had died. At a false discovery rate of 0.05, 33 genes were differentially expressed between patients who did and did not have a subsequent recurrence. Ingenuity pathway analysis demonstrated that one of the top canonical pathways that differed was higher expression of oxidative phosphorylation signature (p<0.001).